Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Daiichi Sankyo
UNICANCER
Hoosier Cancer Research Network
National Institutes of Health Clinical Center (CC)
University Hospital Schleswig-Holstein
Sumitomo Pharma America, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lumos Pharma
Eli Lilly and Company